このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AngioDynamics 将来の成長

Future 基準チェック /06

AngioDynamicsは、76.3%と4.4%でそれぞれ年率76.3%で利益と収益が成長すると予測される一方、EPSはgrowで73.8%年率。

主要情報

76.3%

収益成長率

73.8%

EPS成長率

Medical Equipment 収益成長	16.6%
収益成長率	4.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	22 May 2024

今後の成長に関する最新情報

Recent updates

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why

Oct 28

Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?

Oct 07

AngioDynamics: Focusing On Three Credible Growth Drivers And Targeting Growth Acceleration

Jul 20

業績と収益の成長予測

NasdaqGS:ANGO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
5/31/2027	349	0	N/A	N/A	1
5/31/2026	314	-11	N/A	N/A	1
5/31/2025	287	-43	N/A	N/A	4
5/31/2024	287	-194	N/A	N/A	4
2/29/2024	324	-192	-23	-17	N/A
11/30/2023	330	-14	-7	-3	N/A
8/31/2023	336	6	-5	-1	N/A
5/31/2023	339	-52	-4	0	N/A
2/28/2023	335	-37	-12	-7	N/A
11/30/2022	328	-33	-22	-17	N/A
8/31/2022	321	-33	-28	-23	N/A
5/31/2022	316	-27	-11	-7	N/A
2/28/2022	306	-40	-7	-4	N/A
11/30/2021	303	-38	7	11	N/A
8/31/2021	298	-34	16	21	N/A
5/31/2021	291	-32	19	24	N/A
2/28/2021	273	-169	10	16	N/A
11/30/2020	271	-171	-14	-8	N/A
8/31/2020	268	-170	-21	-13	N/A
5/31/2020	264	-167	-22	-15	N/A
2/29/2020	277	-7	0	7	N/A
11/30/2019	273	-6	27	33	N/A
8/31/2019	273	-7	36	40	N/A
5/31/2019	271	-11	34	37	N/A
2/28/2019	205	-34	33	36	N/A
11/30/2018	223	-16	28	32	N/A
8/31/2018	240	-12	26	29	N/A
5/31/2018	262	-6	38	41	N/A
2/28/2018	343	1	33	37	N/A
11/30/2017	345	-10	N/A	47	N/A
8/31/2017	347	4	N/A	51	N/A
5/31/2017	270	-7	N/A	56	N/A
2/28/2017	356	-25	N/A	55	N/A
11/30/2016	358	-27	N/A	53	N/A
8/31/2016	357	-42	N/A	48	N/A
5/31/2016	351	-44	N/A	45	N/A
2/29/2016	347	-1	N/A	37	N/A
11/30/2015	346	-6	N/A	37	N/A
8/31/2015	349	-5	N/A	25	N/A
5/31/2015	352	-3	N/A	26	N/A
2/28/2015	356	-4	N/A	25	N/A
11/30/2014	358	5	N/A	12	N/A
8/31/2014	354	4	N/A	23	N/A
5/31/2014	351	2	N/A	25	N/A
2/28/2014	346	2	N/A	26	N/A
11/30/2013	340	-3	N/A	37	N/A
8/31/2013	340	0	N/A	40	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ANGO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANGO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ANGO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANGOの収益 ( 4.4% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: ANGOの収益 ( 4.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ANGOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AngioDynamics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 10.0% to US$13.50

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

Price target increased by 12% to US$17.33

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

Recent updates

AngioDynamics: A Story To Monitor

CEO, President & Director recently bought US$67k worth of stock

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Price target decreased by 10.0% to US$13.50

Insufficient new directors

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

Angiodynamics, Inc. Announces Board Changes

Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics: Restructuring Initiative May Not Go Far Enough

AngioDynamics, Inc. Announces Manufacturing Operations Restructuring

David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

Price target increased by 12% to US$17.33

AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023

AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study

CEO, President & Director exercised options and sold US$102k worth of stock

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023

New minor risk - Profitability

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Price target decreased by 22% to US$20.00

Key Executive recently sold US$60k worth of stock

Price target decreased to US$24.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023

AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023

Price target decreased to US$26.50

Insufficient new directors

AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

CEO, President & Director recently bought US$150k worth of stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022

AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

Key Executive recently sold US$112k worth of stock

Executive VP & CFO exercised options and sold US$67k worth of stock

Consensus forecasts updated

Price target decreased to US$31.00

Forecast to breakeven in 2025

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023

AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M

CEO, President & Director exercised options and sold US$176k worth of stock

AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022

Key Executive recently sold US$79k worth of stock

Price target increased to US$36.00

Independent Non-Executive Chairman exercised options to buy US$136k worth of stock.

Insufficient new directors

Independent Non-Executive Chairman exercised options to buy US$140k worth of stock.

Independent Director notifies of intention to sell stock

Consensus forecasts updated